title: The Race Is On To Shorten the Turnaround Time for Diagnosis of Multidrug-Resistant Tuberculosis.
abstract: To realize the most benefit from multidrug-resistant tuberculosis (MDR-TB) screening, all nucleic acid amplification test (NAAT)-positive respiratory specimens should be universally tested. Once an MDR-TB diagnosis is established, additional testing is warranted to provide details about the detected mutations. The lab-on-chip technology described by A. M. Cabibbe et al. (J Clin Microbiol 53:3876-3880, 2015, http://dx.doi.org/10.1128/JCM.01824-15) potentially provides this much needed information.
authors.affiliation: Department of Respiratory Medicine, Skaraborg Hospital, Skövde, Sweden.
authors.forename: Akos
authors.initials: A
authors.lastname: Somoskovi
authors.affiliation: Department of Medicine & Advanced Diagnostic Laboratories, National Jewish Health, Denver, Colorado, USA salfingerm@njhealth.org.
authors.forename: Max
authors.initials: M
authors.lastname: Salfinger
mesh_terms: D006801:Humans; D056656:Lab-On-A-Chip Devices; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis*